Decera Clinical Education Oncology Podcast

In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an  audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:Clinical role of Ki-67 testingCore biopsies for identifying potential benefit with neoadjuvant endocrine therapyCombining CDK4/6 inhibition with tamoxifenPresenters:Javier Cortes, MD, PhDHead, Breast Cancer ProgramIOB Institute of OncologyMadrid and Barcelona, SpainStephen R. D. Johnston, MA, FRCP, PhDProfessor of Breast Cancer MedicineBreast UnitDepartment of MedicineRoyal Marsden HospitalLondon, United KingdomSara Tolaney, MD, MPHAssistant Professor of MedicineHarvard Medical SchoolAssociate DirectorSusan F Smith Center for Women’s CancerDirector of Clinical Trials, Breast Oncology  Director of Breast Immunotherapy  Clinical ResearchSenior PhysicianBreast Oncology ProgramDana-Farber Cancer InstituteBoston, Massachusetts, USAContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including downloadable slides and associated Podcast Pearls PDF:https://bit.ly/37tfvtj Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:Updated safety and patient preference data from the ARAMIS and ODENZA trialsChoice of apalutamide, darolutamide, and enzalutamideCounseling patients on adverse eventsManaging patients with asymptomatic nonmetastatic CRPCPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineGustave RoussyVillejuif, France  Alicia K. Morgans, MD, MPHAssociate ProfessorDivision of OncologyDepartment of MedicineNorthwestern UniversityChicago, Illinois  Link to full program, including downloadable slides:https://bit.ly/36IEnNE Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include:Atrial fibrillationCardiac toxicityMusculoskeletal AEsManaging risk of infectionsPresenter:  Amy Goodrich, RN, MSN, CRNP-AC  Research Associate/Nurse PractitionerSidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandCE/AAPA credit available by visiting the online program:https://bit.ly/3zMXFOpLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include:Patient adherence to oral medicationsLifestyle changesMonitoring, recording, and reporting of AEsThe role of the nurseThe role of the patientAE managementPresenter:  Sandra E. Kurtin, PhD, ANP-C, AOCNDirector, Advanced Practice and Clinical IntegrationThe University of Arizona Cancer CenterAssistant Professor, Clinical MedicineAdjunct Clinical Professor, NursingThe University of ArizonaTucson, ArizonaCE/AAPA credit available by visiting the online program:https://bit.ly/3zMXFOpLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include:PharmacokineticsDrug metabolismDrug–drug interactionsDrug–food interactionsThe role of CYP enzymesFoods to avoidMedication reviewPresenter:Sandra E. Kurtin, PhD, ANP-C, AOCNDirector, Advanced Practice and Clinical IntegrationThe University of Arizona Cancer CenterAssistant Professor, Clinical MedicineAdjunct Clinical Professor, NursingThe University of ArizonaTucson, ArizonaCE/AAPA credit available by visiting the online program:https://bit.ly/3zMXFOpLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:BTK inhibitor selectivityBTK inhibitor adverse event profilesIbrutinib intoleranceManagement of common adverse eventsPresenter:Amy Goodrich, RN, MSN, CRNP-ACResearch Associate/Nurse PractitionerSidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandCE/AAPA credit available by visiting the online program:https://bit.ly/3zMXFOpLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:Rationale for inhibiting BTKMOA of BTK inhibitorsApproved BTK inhibitorsRecent clinical trial findingsLink to full program, including downloadable slidesets:https://bit.ly/3iwN9UbPresenter: Beth Faiman, PhD, MSN, APRN-BC, AOCNNurse PractitionerCleveland Clinic Taussig Cancer InstituteCleveland, Ohio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trialOngoing trials evaluating radionuclides in combination with other agents in metastatic CRPCPresenters:Chris Parker, MDProfessor of Prostate OncologyInstitute of Cancer ResearchClinical OncologistDepartment of Uro-oncologyRoyal Marsden HospitalSutton, Surrey, United KingdomBertrand Tombal, MD, PhDProfessor of UrologyInstitut de Recherche Clinique (IRC)Cliniques universitaires Saint-LucChairmanDepartment of SurgeryCliniques universitaires Saint-LucBrussels, BelgiumLink to full program, including downloadable slides: https://bit.ly/36IEnNE Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:At what time in the treatment journey should CAR T-cell therapy be considered?How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?How is CAR T-cell therapy best used for multiple myeloma?What qualities of bridging therapy are most preferred?When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?  How are steroids optimally used in managing CAR T-cell therapy–related toxicities?Presenters:Caron A. Jacobson, MDAssistant ProfessorDivision of Medical OncologyDepartment of MedicineHarvard Medical SchoolDana-Farber Cancer InstituteBoston, MassachusettsJae H. Park, MDAssociate Member  Leukemia Service and Cellular Therapeutics Center  Memorial Sloan Kettering Cancer CenterNew York, New YorkNoopur Raje, MDDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer Center  Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by an educational grant from Bristol-Myers Squibb.Link to full program:https://bit.ly/3BfbEOf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center.Presenter:  Donna Catamero, ANP-BC, OCN, CCRCAssociate Director, Myeloma Translational ResearchThe Mount Sinai Health SystemNew York, New YorkCE/AAPA credit available by visiting the online program:https://bit.ly/3zMXFOpLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.